SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Stenquist Bo)
 

Sökning: WFRF:(Stenquist Bo) > (2008) > Photodynamic therap...

Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study

Wennberg, Ann-Marie, 1956 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
Stenquist, Bo, 1937 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
Stockfleth, E (författare)
visa fler...
Keohane, S. (författare)
Lear, J.T (författare)
Karolinska Institutet
Jemec, G. (författare)
Mork, C. (författare)
Christensen, E. (författare)
Kapp, A. (författare)
Solvsten, H. (författare)
Talme, T. (författare)
Berne, Berit (författare)
Uppsala universitet,Dermatologi och venereologi
Forschner, T. (författare)
visa färre...
 (creator_code:org_t)
2008
2008
Engelska.
Ingår i: Transplantation. - 0041-1337 .- 1534-6080. ; 86:3, s. 423-9
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • BACKGROUND: Organ transplant recipients on long-term immunosuppressive therapy are at increased risk of non-melanoma skin lesions. Repeated field photodynamic therapy using topical methyl aminolevulinate (MAL) may have potential as a preventive treatment. METHODS: This open randomized, intrapatient, comparative, multicenter study included 81 transplant recipients with 889 lesions (90% actinic keratoses (AK)]. In each patient, the study treatment was initially administered to one 50 cm area on the face, scalp, neck, trunk, or extremities (n=476 lesions) twice (1 week apart), with additional single treatments at 3, 9, and 15 months. On each occasion, the area was debrided gently and MAL cream (160 mg/g) applied for 3 hr, before illumination with noncoherent red light (630 nm, 37 J/cm2). The control, 50 cm2 area (n=413 lesions) received lesion-specific treatment (83% cryotherapy) at baseline and 3, 9, and 15 months. Additionally, all visible lesions were given lesion-specific treatment 21 and 27 months in both treatment and control areas. RESULTS: At 3 months, MAL photodynamic therapy significantly reduced the occurrence of new lesions (65 vs. 103 lesions in the control area; P=0.01), mainly AK (46% reduction; 43 vs. 80; P=0.006). This effect was not significant at 27 months (253 vs. 312; P=0.06). Hypopigmentation, as assessed by the investigator, was less evident in the treatment than control areas (16% vs. 51% of patients; P<0.001) at 27 months. CONCLUSION: Our results suggest that repeated field photodynamic therapy using topical MAL may prevent new AK in transplant recipients although further studies are needed.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)

Nyckelord

Administration
Topical
Adult
Aged
derivatives/therapeutic use
Cryotherapy
Europe
Female
Humans
Immunosuppressive Agents/*adverse effects
Keratosis/chemically induced/pathology/*prevention & control
Male
Middle Aged
*Organ Transplantation
*Photochemotherapy/adverse effects
Photosensitizing Agents/administration & dosage/adverse
effects/*therapeutic use
Treatment Outcome
MEDICINE

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy